Recommendations Developed for Tests to Support Diagnosis of Syphilis
By Elana Gotkine HealthDay Reporter
MONDAY, Feb. 12, 2024 -- In a report issued by the U.S. Centers for Disease Control and Prevention and published online Feb. 8 in the agency's Morbidity and Mortality Weekly Report, recommendations are presented for tests that can support a diagnosis of syphilis, including identification of Treponema pallidum.
John R. Papp, Ph.D., from the CDC in Atlanta, and colleagues note that depending on whether the tests detect antibodies that are broadly reactive to lipoidal antigens shared by both host and T. pallidum or antibodies specific to T. pallidum, the laboratory tests for T. pallidum can be categorized into nontreponemal and treponemal tests, respectively. To help differentiate between an untreated infection or a past infection that has been successfully treated, both types of tests must be used in conjunction. Newer serologic tests allow for laboratory automation but have to be used in an algorithm, which can include older manual serological tests. Direct detection of T. pallidum is continuing to evolve from microscopic examination of materials from lesions to molecular detection of T. pallidum.
"Additional point-of-care tests and data are needed to increase understanding of their performance in clinical and outreach settings," the authors write. "Additional areas needed for research include well-designed prospective studies on point-of-care test performance in the context of screening algorithms, special patient populations, linkage to treatment and care, and cost-benefits so that recommendations can be made regarding performance and use in the United States."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.